BNP Paribas Financial Markets’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $347 | Sell |
46
-4
| -8% | -$28 | ﹤0.01% | 5712 |
|
|
2026
Q1 | $339 | Buy |
50
+1
| +2% | +$8 | ﹤0.01% | 5578 |
|
|
2025
Q4 | $430 | Hold |
49
| – | – | ﹤0.01% | 5489 |
|
|
2025
Q3 | $600 | Buy |
49
+1
| +2% | +$9 | ﹤0.01% | 5296 |
|
|
2025
Q2 | $254 | Sell |
48
-3
| -6% | -$22 | ﹤0.01% | 5268 |
|
|
2025
Q1 | $395 | Sell |
51
-19
| -27% | -$228 | ﹤0.01% | 5160 |
|
|
2024
Q4 | $927 | Sell |
70
-2
| -3% | -$19 | ﹤0.01% | 5094 |
|
|
2024
Q3 | $719 | Sell |
72
-10,169
| -99% | -$153K | ﹤0.01% | 3973 |
|
|
2024
Q2 | $228K | Buy |
10,241
+4,679
| +84% | +$145K | ﹤0.01% | 3055 |
|
|
2024
Q1 | $327K | Sell |
5,562
-4,970
| -47% | -$214K | ﹤0.01% | 3075 |
|
|
2023
Q4 | $233K | Buy |
10,532
+4,433
| +73% | +$66.9K | ﹤0.01% | 3143 |
|
|
2023
Q3 | $132K | Buy |
6,099
+1,699
| +39% | +$66.7K | ﹤0.01% | 3245 |
|
|
2023
Q2 | $297K | Sell |
4,400
-7,385
| -63% | -$3.05M | ﹤0.01% | 2856 |
|
|
2023
Q1 | $5.5M | Buy |
11,785
+6,360
| +117% | +$3.36M | 0.01% | 1194 |
|
|
2022
Q4 | $2.17M | Sell |
5,425
-536
| -9% | -$205K | ﹤0.01% | 1714 |
|
|
2022
Q3 | $1.94M | Sell |
5,961
-1,201
| -17% | -$387K | ﹤0.01% | 1982 |
|
|
2022
Q2 | $1.89M | Buy |
7,162
+2,987
| +72% | +$763K | ﹤0.01% | 1782 |
|
|
2022
Q1 | $1.25M | Sell |
4,175
-1,317
| -24% | -$459K | ﹤0.01% | 2159 |
|
|
2021
Q4 | $1.94M | Buy |
5,492
+1,603
| +41% | +$499K | ﹤0.01% | 2055 |
|
|
2021
Q3 | $994K | Buy |
3,889
+2,109
| +118% | +$747K | ﹤0.01% | 2372 |
|
|
2021
Q2 | $1.18M | Buy |
1,780
+475
| +36% | +$274K | ﹤0.01% | 2076 |
|
|
2021
Q1 | $1.13M | Buy |
1,305
+149
| +13% | +$159K | ﹤0.01% | 2071 |
|
|
2020
Q4 | $1.07M | Sell |
1,156
-392
| -25% | -$412K | ﹤0.01% | 1980 |
|
|
2020
Q3 | $1.59M | Buy |
1,548
+434
| +39% | +$467K | ﹤0.01% | 1607 |
|
|
2020
Q2 | $1.13M | Sell |
1,114
-930
| -45% | -$864K | ﹤0.01% | 1749 |
|
|
2020
Q1 | $1.78M | Buy |
2,044
+881
| +76% | +$876K | ﹤0.01% | 1552 |
|
|
2019
Q4 | $1.25M | Sell |
1,163
-514
| -31% | -$525K | ﹤0.01% | 1914 |
|
|
2019
Q3 | $1.55M | Buy |
1,677
+473
| +39% | +$520K | ﹤0.01% | 1641 |
|
|
2019
Q2 | $1.36M | Sell |
1,204
-58
| -5% | -$63.5K | ﹤0.01% | 1622 |
|
|
2019
Q1 | $1.72M | Buy |
1,262
+600
| +91% | +$814K | ﹤0.01% | 1458 |
|
|
2018
Q4 | $766K | Sell |
662
-4,854
| -88% | -$5.46M | ﹤0.01% | 1682 |
|
|
2018
Q3 | $8.38M | Sell |
5,516
-130
| -2% | -$200K | 0.01% | 910 |
|
|
2018
Q2 | $8.84M | Sell |
5,646
-613
| -10% | -$799K | 0.01% | 846 |
|
|
2018
Q1 | $7.23M | Buy |
6,259
+3,498
| +127% | +$4.61M | 0.01% | 828 |
|
|
2017
Q4 | $3.27M | Buy |
2,761
+2,462
| +823% | +$3.09M | 0.01% | 1219 |
|
|
2017
Q3 | $402K | Buy |
299
+3
| +1% | +$3.16K | ﹤0.01% | 2110 |
|
|
2017
Q2 | $239K | Buy |
296
+253
| +588% | +$176K | ﹤0.01% | 2342 |
|
|
2017
Q1 | $26.5K | Sell |
43
-107
| -71% | -$65.2K | ﹤0.01% | 2947 |
|
|
2016
Q4 | $80K | Sell |
150
-36
| -19% | -$18K | ﹤0.01% | 2630 |
|
|
2016
Q3 | $96K | Buy |
186
+93
| +100% | +$43.8K | ﹤0.01% | 2126 |
|
|
2016
Q2 | $38.3K | Buy |
+93
| New | +$42.6K | ﹤0.01% | 2384 |
|
|
2016
Q1 | – | Sell |
-219
| Closed | -$167K | – | 2808 |
|
|
2015
Q4 | $167K | Sell |
219
-243
| -53% | -$161K | ﹤0.01% | 1587 |
|
|
2015
Q3 | $253K | Buy |
462
+238
| +106% | +$144K | ﹤0.01% | 1793 |
|
|
2015
Q2 | $132K | Buy |
224
+215
| +2,389% | +$125K | ﹤0.01% | 1932 |
|
|
2015
Q1 | $6.81K | Buy |
+9
| New | +$6.98K | ﹤0.01% | 2976 |
|
Other funds holding KYNB
AC
BC
BNP Paribas Financial Markets's KYNB Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Kyntra Bio (KYNB) stake by 8% in Q2 2026, selling an estimated $28 and leaving 46 shares worth $347. The position accounts for ﹤0.01% of the portfolio, ranked #5712.
BNP Paribas Financial Markets first reported a position in KYNB in Q1 2015 and has held it in 45 quarters since. The position peaked at $8.84M in Q2 2018. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.
- BNP Paribas Financial Markets held 46 shares of Kyntra Bio worth $347 as of Q2 2026.
- BNP Paribas Financial Markets sold 4 Kyntra Bio shares in Q2 2026, an estimated $28.
- Kyntra Bio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5712 holding.
- BNP Paribas Financial Markets first reported a position in Kyntra Bio in Q1 2015 and has held it in 45 quarters since.
- BNP Paribas Financial Markets's Kyntra Bio position peaked at $8.84M in Q2 2018.
- 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.